PLAU and cancer: We primarily selected ATN-291 as a candidate for PET imaging development as it could provide real-time global monitoring of uPA/uPAR expression as a whole (instead of specifically targeting only uPA), which could be more relevant for cancer diagnosis and therapeutic response evaluation.